Autor: "Proia DA" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Ganetespib, an HSP90 inhibitor, kills Epstein-Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood.
Autorzy:: Shatzer A; a Laboratory of Infectious Diseases , National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda , MD , USA.
Ali MA; a Laboratory of Infectious Diseases , National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda , MD , USA.
Chavez M; a Laboratory of Infectious Diseases , National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda , MD , USA.
Dowdell K; a Laboratory of Infectious Diseases , National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda , MD , USA.
Lee MJ; b Developmental Therapeutics Branch , National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.
Tomita Y; b Developmental Therapeutics Branch , National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.
El-Hariry I; c Synta Pharmaceuticals , Lexington , MA , USA.
Trepel JB; b Developmental Therapeutics Branch , National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.
Proia DA; c Synta Pharmaceuticals , Lexington , MA , USA.
Cohen JI; a Laboratory of Infectious Diseases , National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda , MD , USA.; Pokaż więcej
Źródło:: Leukemia & lymphoma [Leuk Lymphoma] 2017 Apr; Vol. 58 (4), pp. 923-931. Date of Electronic Publication: 2016 Aug 11.
Typ publikacji:: Journal Article
MeSH Terms:: B-Lymphocytes/*drug effects
B-Lymphocytes/*virology
Epstein-Barr Virus Infections/*blood
Herpesvirus 4, Human/*physiology
T-Lymphocytes/*drug effects
T-Lymphocytes/*virology
Triazoles/*pharmacology
Animals ; Cell Line, Transformed ; Cell Survival/drug effects ; Cells, Cultured ; Disease Models, Animal ; Epstein-Barr Virus Infections/virology ; Epstein-Barr Virus Nuclear Antigens/genetics ; Epstein-Barr Virus Nuclear Antigens/metabolism ; Female ; HSC70 Heat-Shock Proteins/genetics ; HSC70 Heat-Shock Proteins/metabolism ; HSP90 Heat-Shock Proteins/antagonists & inhibitors ; Humans ; Lymphocyte Count ; Mice ; Mice, SCID

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Corrigendum: Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.
Autorzy:: Alexandrova EM
Yallowitz AR
Li D
Xu S
Schulz R
Proia DA
Lozano G
Dobbelstein M
Moll UM; Pokaż więcej
Źródło:: Nature [Nature] 2015 Nov 19; Vol. 527 (7578), pp. 398. Date of Electronic Publication: 2015 Sep 30.
Typ publikacji:: Published Erratum

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.
Autorzy:: Alexandrova EM; Department of Pathology, Stony Brook University, Stony Brook, New York 11794, USA.
Yallowitz AR; Department of Pathology, Stony Brook University, Stony Brook, New York 11794, USA.
Li D; Department of Pathology, Stony Brook University, Stony Brook, New York 11794, USA.
Xu S; Department of Pathology, Stony Brook University, Stony Brook, New York 11794, USA.
Schulz R; Institute of Molecular Oncology, University of Göttingen, 37077 Göttingen, Germany.
Proia DA; Synta Pharmaceuticals Corp., Lexington, Massachusetts 02421, USA.
Lozano G; Department of Cancer Genetics, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Dobbelstein M; Institute of Molecular Oncology, University of Göttingen, 37077 Göttingen, Germany.
Moll UM; 1] Department of Pathology, Stony Brook University, Stony Brook, New York 11794, USA [2] Institute of Molecular Oncology, University of Göttingen, 37077 Göttingen, Germany.; Pokaż więcej
Źródło:: Nature [Nature] 2015 Jul 16; Vol. 523 (7560), pp. 352-6. Date of Electronic Publication: 2015 May 25.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Protein Stability*/drug effects
Lymphoma/*drug therapy
Lymphoma/*metabolism
Molecular Targeted Therapy/*methods
Mutant Proteins/*antagonists & inhibitors
Tumor Suppressor Protein p53/*antagonists & inhibitors
Tumor Suppressor Protein p53/*metabolism
Alleles ; Allografts ; Animals ; Apoptosis/drug effects ; Cell Line, Tumor ; Disease Models, Animal ; Female ; HSP90 Heat-Shock Proteins/antagonists & inhibitors ; HSP90 Heat-Shock Proteins/metabolism ; Histone Deacetylase 6 ; Histone Deacetylases/metabolism ; Humans ; Lymphoma/genetics ; Lymphoma/pathology ; Male ; Mice ; Mutant Proteins/genetics ; Mutant Proteins/metabolism ; Neoplasm Transplantation ; Survival Rate ; Tamoxifen/pharmacology ; Tamoxifen/therapeutic use ; Triazoles/pharmacology ; Triazoles/therapeutic use ; Tumor Suppressor Protein p53/genetics

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Inhibiting heat shock protein 90 (HSP90) limits the formation of liver cysts induced by conditional deletion of Pkd1 in mice.
Autorzy:: Smithline ZB; Yale University, New Haven, Connecticut, 06520, United States of America; Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States of America.
Nikonova AS; Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States of America.
Hensley HH; Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States of America.
Cai KQ; Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States of America.
Egleston BL; Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States of America.
Proia DA; Synta Pharmaceuticals, Lexington, Massachusetts, 02421, United States of America.
Seeger-Nukpezah T; Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States of America; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, 50937, Germany.
Golemis EA; Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2014 Dec 04; Vol. 9 (12), pp. e114403. Date of Electronic Publication: 2014 Dec 04 (Print Publication: 2014).
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:: Cysts/*drug therapy
HSP90 Heat-Shock Proteins/*antagonists & inhibitors
Liver Diseases/*drug therapy
Protein Kinase C/*genetics
Resorcinols/*pharmacology
Triazoles/*pharmacology
Animals ; Cysts/genetics ; Female ; Gene Knockout Techniques ; Liver/drug effects ; Liver/metabolism ; Liver/pathology ; Liver Diseases/genetics ; Male ; Mice, Knockout ; Protein Kinase C/metabolism ; Resorcinols/therapeutic use ; Triazoles/therapeutic use
SCR Disease Name:: Polycystic liver disease

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: WTAP is a novel oncogenic protein in acute myeloid leukemia.
Autorzy:: Bansal H; Greehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, TX, USA.
Yihua Q; Department of Leukemia & Department of Stem Cell Transplantation and Cellular Therapy, The MD Anderson Cancer Center, Houston, TX, USA.
Iyer SP; Methodist Cancer Center, Houston, TX, USA.
Ganapathy S; Greehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, TX, USA.
Proia DA
Penalva LO; 1] Greehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, TX, USA [2] Department of Cellular and Structural Biology, The University of Texas Health Science Center, San Antonio, TX, USA.
Uren PJ; Division of Biological Sciences at University of Southern California, Los Angeles, CA, USA.
Suresh U; Greehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, TX, USA.
Carew JS; Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center, San Antonio, TX, USA.
Karnad AB; Department of Medicine, The University of Texas Health Science Center, San Antonio, TX, USA.
Weitman S; Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center, San Antonio, TX, USA.
Tomlinson GE; Greehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, TX, USA.
Rao MK; 1] Greehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, TX, USA [2] Department of Cellular and Structural Biology, The University of Texas Health Science Center, San Antonio, TX, USA.
Kornblau SM; Department of Leukemia & Department of Stem Cell Transplantation and Cellular Therapy, The MD Anderson Cancer Center, Houston, TX, USA.
Bansal S; Greehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, TX, USA.; Pokaż więcej
Źródło:: Leukemia [Leukemia] 2014 May; Vol. 28 (5), pp. 1171-4. Date of Electronic Publication: 2014 Jan 13.
Typ publikacji:: Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Leukemia, Myeloid, Acute/*genetics
Nuclear Proteins/*genetics
Cell Cycle Proteins ; Humans ; Leukemia, Myeloid, Acute/pathology ; RNA Splicing Factors